The following is a summary of the Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Vaxart reported a revenue of $7.4 million in 2023, an increase compared to $0.1 million in 2022, primarily due to the Bill & Melinda Gates Foundation grant and increased sales of Inavir in Japan.

• The company ended 2023 with cash, cash equivalents, and investments totaling $39.7 million, and raised an additional $15 million in net proceeds in early 2024, estimating a cash runway into the fourth quarter of 2024.

• Vaxart received a $9.27 million contract from BARDA to prepare for a 10,000-subject Phase 2b clinical trial of their oral pill XBB COVID-19 vaccine candidate, potentially beginning in Q2 2024.

Business Progress:

• Vaxart saw growth in their norovirus program and completed two phase 2 studies in 2023.

• The company established proof of concept in two challenge studies for respiratory and gastrointestinal viruses.

• Vaxart progressed with their COVID-19 vaccine program, aiming to produce more effective vaccines against various strains of the virus, with the support of a recent BARDA contract award.

• The company has planned a meeting with the FDA in 2024 over their Phase 2b dose confirmation study and believes they have the most advanced norovirus vaccine candidate in clinical development.

• The company has appointed a new President and CEO, Steve Lo.

More details: Vaxart IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.